Abstract
Patients with atopic dermatitis (AD) may discontinue dupilumab owing to dupilumab-induced ocular adverse events (DOAEs) or dupilumab-induced facial redness (DFR). To evaluate DOAE and DFR outcomes after switching to tralokinumab or Janus kinase inhibitor (JAKi). This retrospective study included 106 patients discontinuing dupilumab because of DOAEs and/or DFR. The primary outcome was the proportion of patients with AE resolution or improvement between dupilumab discontinuation (M0) and 3-6 months of tralokinumab or JAKi (M3-M6) treatment; the secondary outcome was the percentage of patients with controlled AD defined by Investigator's Global Assessment (IGA) scores of 0/1 at M3-M6. Proportions of patients with DOAE (92% vs 72%; p=0.0244) and DFR (85% vs 33%; p=0.0006) resolution or improvement) were higher with JAKi than with tralokinumab. Proportions of patients reaching an IGA score of 0/1 increased from M0 to M3-M6 (22% vs. 42%, p=0.0067) in the JAKi group and remained similar (32% vs. 35%) in the tralokinumab group. However, 57% discontinued the new treatment after 8 months on average, mainly owing to lack of efficacy. JAKi appears to be more efficient than tralokinumab in managing dupilumab-induced AE; however, both strategies may fail to control AD.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
More From: The journal of allergy and clinical immunology. In practice
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
